Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Van Andel Institute and Spectrum Health Form Joint Venture

By Labmedica staff writers
Posted on 26 Mar 2007
Spectrum Health (Grand Rapids, MI, USA) and Van Andel Institute (VAI; Grand Rapids, MI, USA) have announced a US$6 million joint venture that will offer 21st century molecular technologies for investigation of complex diseases like cancer, heart disease, mental illness, and other conditions at the DNA, RNA, and protein levels.

The Center for Molecular Medicine (CMM), which is being created by these two companies, will provide West Michigan with a laboratory that will aid in early diagnoses and enhance personalized medicine. More...
The Center will also attract new opportunities for diagnostics and pharmaceutical companies to conduct trials in a medical and clinical research environment.

Located in the Grand Valley State University (GVSU) Cook-DeVos Center for Health Studies, the CMM combines Spectrum Health's clinical, laboratory, and research resources, and VAI's research expertise and intellectual property with the latest in molecular biological technology.

"To fulfill the mission of the Institute, we must move our findings from the research laboratory to the clinical laboratory. The Center for Molecular Medicine will allow us to do this in an accelerated fashion and positively impact human health,” said David Van Andel, chairman and CEO of Van Andel Institute. We have the research expertise and Spectrum Health has a large patient population which allows us to apply what we're learning directly into the clinical setting.”

"The Center for Molecular Medicine is an investment in the future of health care,” said Richard C. Breon, president and CEO, Spectrum Health. "It accelerates the drive toward personalized medicine--the tailoring of treatment based on molecular make-up.”


Related Links:
Spectrum Health
Center for Molecular Medicine

Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gel Cards
DG Gel Cards
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.